Panacea Pharmaceuticals, Inc

IDT Biologika Corporation, founded in 1921, is a leading global contract development and manufacturing organization (CDMO) specializing in the end-to-end development and manufacturing of viral vaccines, gene immune therapeutics, and sterile injectables. With over 600 employees and substantial investments exceeding 600 million euros, the company leverages over a century of expertise to support pharmaceutical and biotech companies in delivering life-saving treatments worldwide. Headquartered in Rockville, MD, IDT Biologika operates state-of-the-art BSL-2 facilities and offers a full spectrum of services, including process development, viral vector production, and analytical development. Recognized for its commitment to quality and compliance, the company has established itself as a trusted partner for over 200 clinical and commercial projects, continually innovating to meet growing global demands. Generated from the website

Incorporated in 1989, Otsuka America Pharmaceutical is a health care company that commercializes its products throughout North America. It offers products under the ABILIFY Tablets1 and PLETAL Tablets2 brands. The company works in collaboration with Bristol-Myers Squibb, which co-develops and co-promotes ABILIFY. Otsuka America Pharmaceutical has also merged with Meretek Diagnostics to form the Meretek Diagnostics Group under the Medical Device Division of OAPI. It focuses on neuroscience, cardiovascular, oncologic and gastrointestinal therapeutic treatments. The company operates Otsuka Maryland Research Institute, which was established as a wholly-owned subsidiary of OAPI to research and develop a variety of health care products. Otsuka America Pharmaceutical is a part of Otsuka Pharmaceutical Group.

OncoC4 is a pioneering biotechnology company based in Rockville, MD, founded by esteemed immunologists Dr. Yang Liu and Dr. Pan Zheng. The firm is dedicated to advancing innovative cancer therapies, leveraging years of research and the expertise of a skilled leadership team focused on clinical development for patients facing challenging cancers. With a diverse pipeline that includes programs targeting PD-1, VEGF, CTLA-4, and Siglec pathways, OncoC4 is positioned to offer promising treatment options. The company is supported by a robust advisory board and a network of investors and partners committed to transforming the landscape of cancer care. Generated from the website